{"classes":[{"categories":[{"measurements":[{"comment":"Sample size of 3 patients is too small.","groupId":"OG000","lowerLimit":"2.0","upperLimit":"NA","value":"7.9"},{"comment":"Sample size of 2 patients is too small.","groupId":"OG001","lowerLimit":"3.7","upperLimit":"NA","value":"11.6"},{"groupId":"OG002","lowerLimit":"6.0","upperLimit":"13.5","value":"9.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"description":"Overall Survival (OS) listed for all patients by dose level.","dispersionType":"95% Confidence Interval","groups":[{"description":"3 mg/day MLN0128","id":"OG000","title":"Dose Level 1"},{"description":"4 mg/day MLN0128","id":"OG001","title":"Dose Level 2"},{"description":"5 mg/day MLN0128","id":"OG002","title":"Dose Level 3 (MTD)"}],"paramType":"MEDIAN","populationDescription":"* Given the limited sample sizes for Dose Levels 1 \\& 2 (3 \\& 2 patients respectively), the #s presented here may not be statistically valid.\n* Censoring \\& Final OS #s: 1 patient treated at Dose Level 2 and 6 patients treated at Dose Level 3 were censored from OS analysis for withdrawal of consent or lost to follow-up, and were not followed for survival to their death.","reportingStatus":"POSTED","timeFrame":"Up to 4 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}